

Analyst Day Presentation

Prenetics™

December 2021



Disclaimer

This Presentation has been prepared by Arrium Acquisition Corp. ("SPAC") and Phoenix Group Limited (the "Company") in connection with a potential business combination involving SPAC and the Company (the "Transaction") and is preliminary in nature and solely for information purposes and must not be relied upon for any other purpose. This Presentation does not constitute (i) an offer or invitation for the sale or purchase of the securities, assets or business described herein or a commitment of the Company or SPAC with respect to any of the foregoing or (ii) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Transaction, and this Presentation shall not form the basis of any contract, commitment or investment decision and does not constitute either advice or a recommendation regarding any securities. Any offer to sell securities will be made only pursuant to a definitive subscription agreement and will be made in reliance on an exemption from registration under the Securities Act of 1933 (the "Securities Act") for offers and sales of securities that do not involve a public offering.

This Presentation does not purport to contain all information that may be required or relevant to an evaluation of the Transaction, and you will be responsible for conducting your own investigations and analysis that you deem appropriate and for seeking independent advice as to the legal, tax, accounting, financial, credit and other related advice with respect to the Transaction. SPAC and the Company reserve the right to amend or replace this Presentation at any time (but none of SPAC and the Company, their respective subsidiaries, affiliates, legal advisors, financial advisors or agents shall have any obligation to update or supplement any content set forth in this Presentation or otherwise provide any additional information to you in connection with the Transaction should circumstances, management's estimates or opinions change or if information provided in this Presentation becomes inaccurate).

Forward-Looking Statements
This Presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, and also contains certain financial forecasts and projections. All statements other than statements of historical fact contained in the Presentation, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of the Company, market, risk and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including "anticipate," "expect," "intend," "believe," "forecast," "project," "estimate," "target," "seek," "will," "forecast" or other similar expressions. All forward-looking statements are based upon current estimates and forecasts and reflect the views, assumptions, expectations, and opinions of SPAC and the Company as of the date of this Presentation, and are therefore subject to a number of factors, risks and uncertainties, some of which are not commonly known to us. Some of these factors include, but are not limited to, the success of the new product or service offerings of the Company and its subsidiaries (the "Group"), the Group's ability to attract new and retain existing customers, competitive pressures in the industry in which the Group operates, the Group's ability to achieve profitability despite a history of losses, the Group's ability to implement its growth strategies and manage its growth, the Group's ability to meet customer expectations, the Group's ability to produce accurate forecasts of its operating and financial results, the Group's internal controls, fluctuations in foreign currency exchange rates, the Group's ability to raise additional capital, media coverage of the Group, changes in the regulatory environment of the countries in which the Group operates, general economic conditions in the countries in which the Group operates, the Group's ability to attract and retain senior management and skilled employees, the success of the Group's strategic alliances and acquisitions, changes in the Group's relationship with its current customers, suppliers and service providers, disruptions to information technology systems and networks, the Group's ability to protect its brand and reputation, the Group's ability to protect its intellectual property, potential and future litigation that the Group may be involved in, taxes or other liabilities that may be incurred or required subsequently to, or in connection with, the consummation of the Transaction, the foregoing list of factors is not exhaustive. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

In light of these factors, risks and uncertainties, any estimates, assumptions, expectations, forecasts, views or opinions set forth in this Presentation should be regarded as indicative, preliminary and for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of this Presentation and the "Risk Factors" section of the proxy statement/prospectus on Form F-4 relating to the Transaction, which has been filed with the U.S. Securities and Exchange Commission ("SEC"), and other documents filed from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual results and results to differ materially from those contained in the forward-looking statements. SPAC and the Company assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible to predict all risks, or assess the impact of all factors on the Company's business or the extent to which any factor, or combination of factors, may cause the Company's actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition. In addition, the analyses of SPAC and the Company contained herein are not, and do not purport to be, appraisals of the securities, assets or business of the Company, SPAC or any other entity. There may be additional risks that neither SPAC nor the Company presently know or that SPAC and the Company currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's and SPAC's assessment as of any date subsequent to the date of this Presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Industry and Market Data
This Presentation also contains information, estimates and other statistical data derived from third party sources (including Frost & Sullivan). Such information involves a number of assumptions and limitations and due to the nature of the techniques and methodologies used in market research, and Frost & Sullivan cannot guarantee the accuracy of such information. You are cautioned not to place undue weight on such estimates. Neither SPAC nor the Company has independently verified such third party information, and makes no representation, express or implied, as to the accuracy, completeness, timeliness, reliability or availability of such third party information. SPAC and the Company may have supplemented such information where necessary, taking into account publicly available information about other industry participants.

Use of Projections and Historical Financial Information
The 2019 and 2020 historical financial data included in this Presentation has been derived from Phoenix's Limiteds 2019 and 2020 financial statements prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IASB") and are subject to updates based on an ongoing external audit in accordance with the Public Company Accounting Oversight Board standards. In addition, the Company's quarterly financial data included in this Presentation is based on financial data derived from the Company's management accounts that have not been reviewed or audited and are subject to further review and updates. This Presentation contains financial forecasts for the Company with respect to certain financial results for the Company's fiscal years 2021 through 2025 for illustrative purposes. Neither SPAC nor the Company's independent auditors have audited, studied, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this Presentation, and accordingly, they did not express an opinion or provide any other form of assurance with respect thereto for the purpose of this Presentation. These projections are forward-looking statements and should not be relied upon as being necessarily indicative of future results. In this Presentation, certain of the above-mentioned projected information has been provided for purposes of providing comparisons with historical data. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. While such information and projections are necessarily speculative, SPAC and the Company believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection extends from the date of preparation. Accordingly, there can be no assurance that the prospective results are indicative of the future performance of the Company or that actual results will not differ materially from those presented in the prospective financial information. Inclusion of the prospective financial information in this Presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved. All subsequent written and oral forward-looking statements concerning the Company and SPAC, the Transaction or other matters and attributable to the Company and SPAC or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above.

Non-IFRS Financial Measures
This Presentation also includes references to non-IFRS financial measures, such as the Company's Adjusted EBITDA for 2019 and 2020. Such non-IFRS measures should be considered only as supplemental to and not as superior to, financial measures prepared in accordance with IFRS. SPAC and the Company believe these non-IFRS measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. SPAC and the Company believe that the use of these non-IFRS financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in and in comparing the Company's financial measures with other similar companies, many of which present similar non-IFRS financial measures to investors. Management does not consider these non-IFRS measures in isolation or as an alternative to financial measures determined in accordance with IFRS. These non-IFRS financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are added or included in determining these non-IFRS financial measures. Additionally, to the extent that forward-looking non-IFRS financial measures are provided, they are presented on a non-IFRS basis without reconciliations due to the inherent difficulty of forecasting and identifying certain amounts that are necessary for such reconciliations.

Additional Information
In connection with the Transaction, Phoenix Global Limited ("PhxCo") has filed with the SEC a registration statement on Form F-4 (the "Registration Statement") that includes a prospectus with respect to PhxCo's securities to be issued in connection with the Transaction and a proxy statement with respect to the shareholder meeting of SPAC to vote on the Transaction. After the Registration Statement is declared effective, the definitive proxy statement/prospectus will be mailed to all SPAC shareholders as of a record date to be established for voting on the Transaction and other matters as may be described in the Registration Statement. The Company and SPAC will also file other documents regarding the Transaction with the SEC. SPAC shareholders and other interested persons are urged to carefully read the proxy statement/prospectus and any other relevant documents that or that will be filed with the SEC in connection with the Transaction as they become available because, among other things, they will contain updates to the financial, industry and other information herein as well as important information about SPAC, the Company, PhxCo and the Transaction. Shareholders will be able to obtain a free copy of the Registration Statement, including the proxy statement/prospectus, and other documents filed with the SEC, without charge, at the SEC's website located at www.secdoc.gov.

Participants in the Solicitation
SPAC, the Company and PhxCo and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from SPAC's shareholders in connection with the Transaction. Information about the directors and executive officers of SPAC and their ownership is set forth in SPAC's filings with the SEC, including its final prospectus dated May 13, 2021 and subsequent filings on Form 10-G and Form 3. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of SPAC shareholders in connection with the Transaction are or will be set forth in the Registration Statement. You may obtain free copies of the Registration Statement, including the proxy statement/prospectus, as described in the preceding paragraph. The definitive proxy statement will be mailed to shareholders as of a record date to be established for voting on the Transaction when it becomes available.

Trademarks
This Presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this Presentation may be listed without the TM, SM or ® symbols, but such references are not intended to indicate, in any way, that SPAC or the Company will not assert, to the fullest extent under applicable law, their rights or the right of the applicable licensor to such trademarks, service marks, trade names and copyrights. Neither SPAC, the Company, nor any of their respective directors, officers, employees, affiliates, advisors, representatives or agents, make any representation or warranty of any kind, express or implied, as to the value that may be realized in connection with the Transaction, the legal, regulatory, tax, financial, accounting or other effects of the Transaction or the accuracy or completeness of the information contained in this Presentation, and none of them shall have any liability based on or arising from, in whole or in part, any information contained in, or omitted from, this Presentation or for any other written or oral communication transmitted to any person or entity in the course of its evaluation of the Transaction, and they expressly disclaim any responsibility or liability for direct, indirect, incidental, exemplary, consequential, punitive, special or consequential damages, costs, expenses, legal fees or losses (including lost income or profits and opportunity costs) in connection with the use of the information herein.

By accepting this Presentation, the recipient will be deemed to have acknowledged and agreed to the foregoing.

Presenters



Danny Yeung
Group CEO & Co-Founder



Ben Cheng
CEO of Artisan Acquisition Corp.



Stephen Lo, CPA, CFA
Chief Financial Officer



Avi Lasarow
CEO – EMEA



Mike Ma, PhD
Chief R&D Officer



Frank Ong, MD
Chief Medical officer


Time	Duration	Topic	Speaker
8:00-8:10am HKT 7:00-7:10pm EST	10 min	Opening Remarks	Danny Yeung <i>Group CEO & Co-Founder</i>
8:10-8:20am HKT 7:10-7:20pm EST	10 min	Artisan's Investment Thesis	Ben Cheng <i>CEO of Artisan Acquisition Corp</i>
8:20-8:45am HKT 7:20-7:45pm EST	25 min	Vision and Business Updates Prenetics EMEA Overview	Danny Yeung <i>Group CEO & Co-Founder</i> Avi Lasarow <i>CEO – EMEA</i>
8:45-9:25am HKT 7:45-8:25pm EST	40 min	Product Pipeline and Technology	Mike Ma, PhD <i>Chief R&D Officer</i> Frank Ong, MD <i>Chief Medical officer</i>
<i>10 Minute Break</i>			
9:35-9:55am HKT 8:35-8:55pm EST	20 min	Financial Summary	Stephen Lo <i>Chief Financial Officer</i>
9:55-10:25am HKT 9:55-9:25pm EST	20 min	Commercialization and Strategy (Live Product Demo)	Danny Yeung <i>Group CEO & Co-Founder</i>
10:25-11:00am HKT 9:25-10:00pm EST	35 min	Closing Remarks and Q&A	Danny Yeung <i>Group CEO & Co-Founder</i>

Today's Agenda



Opening Remarks

Prenetics is Building the Future of Healthcare



Understanding Prenetics in 5 Questions

- 1**
What Problem Are We Solving?
 - Current healthcare system is dysfunctional, often too reactive and centralized which results in the lack of accessibility, quality and affordability.
 - Prenetics' innovative solutions focus on a patient-first model by providing decentralized testing and digital health services at Point-of-Care and for use at-home.
- 2**
How Do We Do It?
 - Through 3 different pillars of our business units from Prevention, Diagnostics and Personalized Care. We further intend to integrate telehealth services to make it easy for anyone, anywhere to get access to innovative health solutions.
- 3**
What Have We Accomplished?
 - We continue to scale at an impressive rate, with 1H 21 revenues at US\$136.5m, up 1,039% year-over-year. We expect to exceed our FY21 revenue target of US\$205m.
 - We grew from a small laboratory of 11 people in 2014 to now being a leading diagnostics and genomics testing company in UK and Hong Kong with more than 700 employees globally in 9 locations.
- 4**
How Will We Grow?
 - By launching new pipeline products into our existing markets and by entering into new geographies including the United States, Europe and Southeast Asia.
 - With acquisitions which fit into our vision of decentralizing of healthcare. These acquisitions include digital health, rapid diagnostics and clinical laboratories globally.
- 5**
What Is The Potential?
 - We have the opportunity to build a health eco-system comprising of the best in technology and delivering value to millions of patients around the world.
 - With the proceeds of our impending business combination and aligned vision, we have the opportunity to make Prenetics from a billion dollar startup to a ten billion dollar enterprise.



Artisan's Investment Thesis

Adrian Cheng Led Team Backed by Strong Independent Directors

ARTISAN ACQUISITION CORP.



Dr. Adrian Cheng
Founder of Artisan Acquisition Corp.



Ben Cheng
Chief Executive Officer of Artisan Acquisition Corp.



William Keller
Independent Director



Mitch Garber, C.M.
Independent Director



Frank Yu
Independent Director



Sean O'Neill
Independent Director



Prenetics is a Clear Fit for Artisan Acquisition Corp.

Target Criteria – Clearly Met by Prenetics

- ✓ Focus on disruptive lifestyle technologies in healthcare, consumer, technology
- ✓ Strong fundamentals with significant value creation opportunities
- ✓ Well-positioned to deliver value and synergies in the group's global cultural ecosystem
- ✓ Growth upsides through tapping global consumers' unmet demands and burgeoning markets

Prenetics
Investment Thesis for
ARTISAN
ACQUISITION CORP.

- 1 **Disrupting & decentralizing** global healthcare with large global opportunity of over **US\$1.3trn¹**
- 2 **Strong R&D and product innovation capabilities** backed by experienced in-house team, strategic collaboration with Oxford University and vibrant **scientific ecosystem**
- 3 **First-mover advantage** in target geographies with **robust product pipeline and high growth potential**; well positioned to replicate U.S. success stories in its target geographies
- 4 **Inspirational founder** backed by **strong leadership team** of tech, biotech, healthcare and consumer veterans
- 5 **Strong financial profile** and **highly attractive expected valuation** relative to peers

Source: Frost & Sullivan. Notes: 1. Global opportunity as of 2030; represents global market sizes and target addressable markets, except for colorectal cancer screening which does not include mainland China.

Significant Synergies—Prenetics and Adrian Cheng's Ecosystem

Significant Synergies

- Healthcare channel and user access
- Broad network of locations covering healthcare, retail, hospitality and other sectors
- Extensive customer, user, and fan base across platforms
- Direct corporate use cases across eco-system




Transaction Summary

Transaction Overview¹

- Illustrative enterprise value of \$1.25 billion
- Artisan Acquisition Corp. to merge with Prenetics
 - An implied multiple of 4.6x 2022E Revenue and 4.1x 2023E Revenue
- Concurrent with the transaction, \$60mm raised in the form of forward purchase agreements ("FPAs") from Aspex and PAG, in addition to another \$60mm raised in a PIPE from Lippo, Dragonstone, Xen Capital and others at \$10.00 per share
- 100% of Prenetics existing shareholders roll into the new entity. No existing shareholders are exiting
- Proceeds to be used for strategic acquisition or investments, R&D, product roll out, geographic expansion and general corporate purposes

Illustrative Ownership¹



Illustrative Enterprise Value¹

Share Price	\$10.00
Shares Outstanding (mm)	170.92
Illustrative Post-Money Equity Value	\$1,709
(-) Net Cash to Balance Sheet ³	\$455
Illustrative Enterprise Value	\$1,254
EV / 2022E Revenue	4.6x
EV / 2023E Revenue	4.1x

Illustrative Sources & Uses

Assumes 0% redemption by SPAC Shareholders

Sources		Uses	
Existing Target Shareholder Equity Rollover	\$1,150	Existing Target Shareholder Equity Rollover	\$1,150
Sponsor Promote ⁴	100	Sponsor Promote ⁴	100
Cash Available in SPAC Trust Account	339	Transaction Expenses	40
Forward Purchase Agreement	60	Net Cash to Balance Sheet	419
PIPE	60		
Total Sources	\$1,709	Total Uses	\$1,709

Notes: USD/HKD FX rate of 7.78; 1. Excludes (i) the impact of any equity awards issued at or after the closing of the transaction, (ii) the dilutive impact of 18.7mm warrants (11.3mm SPAC public warrants, 5.9mm of sponsor warrants, 1.5mm of FPA warrants) with a strike price of \$11.50 per share, and (iii) the impact of shares with super-voting rights. Includes 9.98mm total Class B ordinary shares; 2. Includes SPAC directors; 3. Includes net cash to balance sheet of \$419mm post the transaction, and Prenetics balance sheet net cash of \$35.4mm, the pro-forma amount of which includes a cash balance of \$9.4mm as of 1Q 2021 and \$26.0mm of proceeds from pre-IPO fundraising; 4. Includes total 9.13mm Class B ordinary shares held by the Sponsor, 0.75mm Class B ordinary shares held by the FPA providers, and 0.1mm Class B ordinary shares held by SPAC directors.

Our Mission

We decentralize healthcare

We seek to decentralize healthcare by making the three pillars **Prevention, Diagnostics and Personalized Care** comprehensive and accessible to anyone, at anytime and anywhere.

Private and Confidential

Prenetics

Decentralizing Healthcare

Prevention


Consumer genetic testing and early colorectal cancer screening

Global Opportunity: **US\$117 Billion+¹**

Personalized Care

Personalized nutrition, hair & sexual health products

Global opportunity: **US\$376 Billion+²**



Diagnostics

Covid-19 testing, POCT / At-home diagnostic testing and medical genetic testing

Global opportunity: **US\$849 Billion+³**

Source: Frost & Sullivan. Notes: Global opportunity as of 2030. 1. Represents global target addressable market for early colorectal cancer screening (except for mainland China) and global market size for consumer genetic testing. 2. Represents global target addressable market for hair loss and erectile dysfunction and global market size for personalized nutrition. 3. Represents global market size for medical device. 4. Represents each business segment revenue as % of total revenue expected in 2025.

Prenetics Today

Leading
Diagnostics / DNA testing company in HK and UK

11 Labs
7 mobile / airport labs in HK & UK and 4 fixed labs

700+
Total Employees

6M+
Total tests processed¹

\$85M
Lifetime Fundraising
K11, Alibaba Group, Tencent, Pinduoduo, JD.com, Meituan, etc.

\$205M
2021E Revenue

Prenetics Competitive Moat

Prevention

- Circle** Whole exome sequencing with proprietary 31mm DNA datapoint algorithm
- Circle** The only NMPA approved non-invasive FIT-DNA colorectal cancer screening test
- Project Screen** Covid-19 PCR test enabled by in-house developed, cloud-based, automated end-to-end solution with capability to perform over 40K tests daily

Diagnostics

- OX-LAMP** Covid-19 rapid testing developed by the University of Oxford, utilizing NAAT
- Circle** Patent pending POC & at-home rapid detection health monitoring system (e.g. Covid-19 & other infectious disease testing²)
- Circle** On-going development of at-home blood based testing for routine health check

Source: Frost & Sullivan. Notes: 1. Include Circle DNA and Covid-19 tests; as of October 31, 2021. 2. Assays to 15 test other infectious diseases are currently under development.

Strong Financial Growth with Diversified Footprint

Exceptional Growth Momentum




Primarily driven by increased demand for laboratory testing, including travel related COVID-19 testing

Diversified Footprint



High Operating Efficiency with Profitable Margins




Well Capitalized



Private and Confidential

Notes: 1. Adjusted Gross Profit represents gross profit before deduction of depreciation and amortization expenses. 2 Adjusted EBITDA represents net profit (loss) before depreciation, amortization, net finance income / (expenses), ESOP or share-based compensation, other non-operating expense including impairment expenses and foreign exchange gains or losses, and income tax.

Global Presence with Operations in 9 Locations



Strategic R&D Collaboration with Oxford University

OSCAR – Oxford Suzhou Centre for Advanced Research

- Key research directly with the only overseas research centre by Oxford
- Initial focus will be on
 - a) HealthPod general development
 - b) HealthPod for Clinicians development



Prenetics Molecular Diagnostics Research Center at Oxford University

- Combined research with Oxford University enables Prenetics to have its own research centre at Oxford University
- Prenetics R&D team already works closely with Oxford team of Professors, with collaboration further enabling us to commercialize novel inventions
- Prenetics' ROFR to acquire technology / IP

Oxford University 3-Year Research Grant

- Key research directly with Oxford and the team of professors from March 2021
- Initial focus:
 - a) Improving sensitivity and time to results of Covid-19 reagent
 - b) Development of enzymes to lower cost
 - c) Assay development (e.g. infectious disease, STD)



Close Collaboration with Prenetics In-house R&D Teams



Dr. Lawrence Tzang, Ph.D.
Co-founder & Chief Scientific Officer
Scientific & Laboratory team



Dr. Senthil Sundaram, M.D.
Chief Clinical Officer
Clinical & Bioinformatician team



Dr. Mike Ma, Ph.D.
Chief R&D Officer
Clinical R&D team



Dr. Peter Wong, DPhil
Chief Technology Officer
Engineering & Development team



Frank Ong, MD
Chief Medical Officer
Circle Snapshot R&D & Setup



Dame Caroline Wilson (British ambassador to China) at OSCAR opening – June 2021
Private and Confidential

World-class Leadership Team of Tech, Biotech, and Healthcare Pioneers

Management Team



Danny Yeung
Group CEO & Co-Founder

GROUPON SXE VENTURES



Stephen Lo, CPA, CFA
Chief Financial Officer

CITI EY



Lawrence Tzang, PhD
Chief Scientific Officer & Co-Founder

CITYU



Avi Lasarow
CEO – EMEA

DNAfit CITI



Mike Ma, PhD
Chief R&D Officer

ENACT SCIENCES HOLOGIC



Frank Ong, MD
Chief Medical Officer

everlywell illumina

Key Scientific Advisers



Prof. Zhanfeng Cui
Donald Pollock Professor of Chemical Engineering, University of Oxford

OXFORD



Prof. Wei Huang
Associate Professor in Dept. of Engineering Science, University of Oxford

OXFORD



Dr. Monique Andersson
Medical Advisor, Director of Microbiology, Oxford University Hospitals, NHS Foundation Trusts

OXFORD UNIVERSITY HOSPITALS NHS




Prof. Michael Yang
Chair Professor of Biomedical Sciences, Vice-President (R&D) City University of Hong Kong


CITYU

Prenetics EMEA Presence

The Prenetics EMEA Story



Prenetics EMEA 2021 Summary




Blue Chip Clientele of Corporates

Airports / Airlines	Cruises	Productions	Sports	Govt	Corporate

Notes: 1. As October 31, 2021.

Prenetics EMEA Capabilities



8

6 Mobile / Airport Labs in UK, and 2 Fixed Labs

Lab Integrations (Europe)

Italy, Ireland, Copenhagen


Care Quality Commission

ISO 27001
ISO 15189
ISO 22870

Six

Sigma Fulfilment House with strong last mile proposition

24x7

Call Centre with Telehealth enabled

Private and Confidential



Product and Technology

Prevention

Prevention



Leading Brand

In Asia and UK consumer genomics

45-50x

More data than the competitors

120k+

CircleDNA tests delivered since July 2019 launch

\$16bn+

Global Market Size¹

\$19mm

2021E CircleDNA Projected Revenue

34%

2020A-2025E Revenue CAGR

CircleDNA
One of The World's Most Comprehensive Consumer DNA Test


Source: Frost & Sullivan; Notes: 1. Global market size for DTC molecular testing services based on projection for 2030; Covid-19 testing service market is not included while influence of Covid-19 has been considered in the market sizing.
Private and Confidential

CircleDNA — An All-New Industry Standard in Genetic Testing

Genotyping Technology

- **High false negative rate:** Will miss >90% mutations associated with cancer and disease
- **Pre-defined** and specific SNP Readings
- **Limited Data**, can only resolve single letter “typos”
- **Static**, will need to test again as science evolves

DNA Data Points



Our Next Generation - Whole Exome Technology

- Read protein-coding genes
- Clinical-grade consumer testing
- 45–50x more data over genotyping
- One test, a Lifetime of Value
- Identify up to 90% genetic variants associated with cancer and other disease



CircleDNA – the Forefront of Health Diagnostics & Disease Prevention Covering Screening, Wellness, Proactive and Preventive Measures

500+ Reports Discovered Across 20 Categories


Family Planning & Disease
375 reports

Diet, Wellness, Lifestyle
69 reports

Traits
70 reports



A Snapshot of CircleDNA Tests



Private and Confidential

DTC Testing – Comparison of Whole Exome Sequencing and Genotyping

Whole Exome Sequencing (WES) vs. Genotyping


WES, an advanced technology for sequencing exome and identifying gene variations in the protein-coding region, **is a relatively comprehensive and efficient method to identify possible pathogenic mutations**. By thoroughly scanning through the exome region and identifying potential mutations associated with cancers and other diseases, **WES is able to empower disease diagnosis substantially**. Therefore, whole exome technology for analysis of variants in coding regions may be a powerful tool in disease diagnosis.

Genotyping Technology

- **High false positive and negative rate:** Will miss most mutations associated with cancer and disease.
- **Pre-defined and specific SNP Readings:** Probes are all designed based on the known SNPs, therefore most variants identified are common variants
- **Limited Data:** Low-frequency mutations and new mutations can not be identified.
- **Mutation sites are located in regulatory region:** Most of the identified sites related with disease are located in the intergenic region and introns
- **Static:** Will need to test again as science evolves

Whole Exome Technology

- **Reading protein-coding genes:** WES is an efficient sequencing approach which focuses only on the protein-coding regions of the genome, in which most known disease-causing genes are presented. This is accomplished by a process called exome enrichment, during which the exome or relevant regions of interest are isolated for WES analysis
- **More data over genotyping:** Deep sequencing of whole exome technology can find low-frequency mutations, rare mutations with the likelihood of occurrence below 1% and new mutation sites associated with cancer and disease
- **Clinical-grade consumer testing:** The direct detection of genetic variants locates pathogenic gene in exonic regions which qualifies it with high-standard identification to serve consumers with clinical grade testing
- **One test can provide comprehensive understanding of whole exome.**



Source: Frost & Sullivan.

Prevention



96%

Sensitivity -
Highly Accurate

**Cost
Effective**

Comparing to
Colonoscopy

**Successful
Model**

Comparable to
ColoGuard
in the US

\$101bn+

Addressable
market¹

ColoClear

The Only Non-Invasive Colon
Cancer Screening Test Approved
by NMPA

Launching in 1H 2022E

Source: Frost & Sullivan. Notes: 1. Global target addressable market for colorectal cancer screening based on projection for 2030, except for mainland China; target population is the age group of 40-74 years old. **Private and Confidential** 29

Early Colorectal Cancer Screening – Overview

	Imaging	Stool-based Test	
	Colonoscopy	FOBT/FIT	FIT-DNA
Advantages	<ul style="list-style-type: none"> ✓ Gold standard for colorectal cancer diagnosis and is also often used for screening purposes ✓ Visualization ✓ Able to apply resection and biopsy ✓ High sensitivity and specificity ✓ Requires less frequent screening 	<ul style="list-style-type: none"> ✓ Non-invasive ✓ Low price ✓ Better compliance than colonoscopy 	<ul style="list-style-type: none"> ✓ Non-invasive ✓ No dietary restrictions or bowel preparation ✓ Superior clinical performance (e.g. sensitivity, specificity, and PPV) than FIT
Disadvantages	<ul style="list-style-type: none"> • Invasive and inconvenient • Lack of professional colonoscopy surgeons and anesthetists to operate in China • Not suitable for specific population with other underlying diseases 	<ul style="list-style-type: none"> • Low sensitivity • Multiple attempts for sampling required • FOBT may require dietary restrictions 	<ul style="list-style-type: none"> • Higher price than FOBT/FIT • 5 days turnaround time
Application Scenario	<ul style="list-style-type: none"> • Hospital 	<ul style="list-style-type: none"> • Hospital • Clinic • At-home 	<ul style="list-style-type: none"> • Hospital • Clinic • At-home

• Colonoscopy procedures and FOBT/FIT are the two key technologies for colorectal cancer screening. Currently colonoscopy is still the gold standard for colorectal cancer diagnosis but has complicated process and poor patient compliance. FIT-DNA as one of the Stool-based tests, is non-invasive, painless and convenient. When FIT-DNA testing results are positive, further colonoscopy screening is required, which improves patient compliance and screening rate in early colorectal cancer screening, providing a better way for scientific and personalized early colorectal cancer screening

Early Colorectal Cancer Screening – Comparison of Stool-based Test

	Stool-based Test		
	FOBT	FIT	FIT-DNA
Detection Object	Occult blood in stool	Occult blood in stool	Detect colorectal neoplasia associated with DNA markers and the presence of occult hemoglobin
Detection Principle	Small samples of stool are placed on the cards and the guaiac causes the stool sample to change color	An antibody that binds to a blood protein called hemoglobin is used to detect any blood	Combines the FIT with a test that detects altered DNA in the stool
Sensitivity	62-79%	79-88%	>92%
Specificity	87-96%	91-93%	87%
Ability to Detect Precancerous Lesions	No	No	Yes

- Despite being considered as the "gold standard" for colorectal cancer diagnosis, colonoscopy requires a relatively complicated process to administer and receives poor patient compliance due to its invasive nature. As a relatively new screening strategy, FIT-DNA combines FIT with testing for altered DNA biomarkers in cells exfoliated into the stool. Compared with FIT alone, FIT-DNA has a higher sensitivity rate for detecting colorectal cancer. In addition, the clinical trial results of FIT-DNA also demonstrate its ability to detect advanced precancerous lesions such as advanced adenomas as small as one centimeter in diameter
- Moreover, FIT-DNA test enables users to collect samples at home, which eases the burden to visit hospitals. Because of its reliable performance and convenience, FIT-DNA is recognized as the best available noninvasive colorectal cancer screening technology. FIT-DNA has been recommended in cancer screening guidelines in the U.S., an example of which is an updated recommendation statement for colorectal cancer screening issued by the U.S. Preventive Services Task Force

Source: Frost & Sullivan.

ColoClear – Industry Leading Performance

FIT-DNA has higher sensitivity when comparing with other non-invasive Colon Cancer screening tests.

Non-invasive Tests	Sensitivity		Specificity	Detection limitations	Sample size needed	Dietary restrictions
	CRC	AA				
gFOBT (Hemoccult II)	40%	12%	98%	Intermittent bleeding	3 bowel movements	Yes
FIT (Faecal Immunochemical Test)	70%	22%	95%	Intermittent bleeding	Single sample	No
EXACT SCIENCES FIT-DNA (ColoGuard)	92%	42%	87%	CRC and AA continuously exfoliate cells	Single sample	No
Prenetics FIT-DNA (ColoClear)	96%	64%	87%	CRC and AA continuously exfoliate cells	Single sample	No

Diagnostic Invasive Test	Sensitivity		Specificity
	CRC	AA	
Colonoscopy	>95%	95%	90%



Closest CRC sensitivity to actual colonoscopy standards

Sensitivity = True positive / (True positive + False negative) * 100%;
 Specificity = True negative / (True negative + False positive) * 100%.

Source: Company filings, Colorectal cancer development and advances in screening. Clin Interv Aging. 2016 July 19; 967-976.



Product and Technology

Diagnostics

Diagnostics



Prenetics laboratory inside Hong Kong International Airport

Project Screen

Covid-19 Testing



Source: Frost & Sullivan.
Notes: 1. As October 31, 2021. 2. Based on projection for 2021; represents global market size; only consists of tests performed in independent clinical laboratories.


Major COVID-19 Testing Technologies Comparison

	Nucleic Acid Amplification Test (RT-LAMP)	Nucleic Acid Amplification Test (RT-PCR)	Antigen Test (Proteins)
Speed	✓ Reaction time: 15 – 20min	✗ Reaction time: 4 – 6 Hours	✓ Reaction time: 15 - 30min
Accuracy	✓ Higher: 96%	✓ Highest: 99%	✗ Symptomatic: 90% or above Asymptomatic: 27%
Mobility & Lab Required	✓ No Need Laboratory No Lab Technicians	✗ Need Laboratory Lab Technicians	✓ No Need Laboratory No Lab Technicians
Availability	✓ Yes	✓ Yes	✓ Yes
Use-Case	✓ Symptomatic & Asymptomatic	✓ Symptomatic & Asymptomatic	✗ Symptomatic (7 days of infection)
Through-put & Scalability	✓ Highly Scalable	✗ Not scalable	✓ Highly Scalable

PCR-Quality Technology from Oxford

Source: Frost & Sullivan.

Game Changing POC / At-Home PCR-Quality Testing Technology from Oxford University




Approvals / Recognitions

- ✓ MHRA² in UK
- ✓ CE IVD³ in EU for POC use
- Application for US FDA in process; Expected by 1H 2022



Inside Oxford Lab
Developing 30-minute



Notes: 1. Reaction time. 2. Medicines and Healthcare products Regulatory Agency. 3. Approved CE Marketing on In-Vitro Diagnostic medical devices.

Circle HealthPod

Rapid Detection System
For **Covid-19**

Source: Company Website. Please view Circle HealthPod Product video here: <https://circlepod.co/>.

Diagnostics



Detects Covid-19 with NAAT
PCR-Quality Technology



Future Assays:

- Influenza / Flu
- STDs




Circle HealthPod A Lab. In Your Pocket

Officially Launched in Hong Kong Nov 2021
Expected to be launched in the EU, the US, and Southeast Asia

Source: Frost & Sullivan. Notes: 1. Represents global market size for medical device based on the projection for 2030. 2. According to trials done primarily by professors and scientists of University of Oxford.

Illustrative Representation of HealthPod Manufacturing Process

Level of vertical integration varies based on OEM, technology, and platform



Near-term Regulatory Roadmap



Obtained **CE-IVD mark for professional use**.
In preparation to apply for EU notified body assessment as required by **EU IVDD¹** to certify **Circle HealthPod for home use**



In preparation to obtain **Emergency Use Authorization "EUA"** from **US FDA**, having commenced a clinical validation and completed a usability study with **UserWise Inc.²**

Other Regions
(including SEA / India / South Africa)

In preparation to obtain **relevant authorizations, licenses and registrations** to distribute **Circle HealthPod**

Notes: 1. European Union Directive 98/79/EC. 2. US based consulting firm focused on US FDA compliance, regulatory approval and usability engineering services for medical products.

Diagnostics



Circle SnapShot

Health Check. At Home.

Launching in 2022E


Source: Frost & Sullivan. Notes: 1. Global market size for at-home health testing based on projection for 2030; does not include home testing kits which do not require lab tests; Covid-19 at-home test has not been considered.

How it works




Activate Kit

Customer purchases online or in-store, registers a Circle account, and activate kit in App




Collect

Customer collect blood samples with self-administered test kit



Return

Patient return sample kit back to the lab



Results

Receive results in ~7 business days. Patient receive report via Circle App, and download lab results to share with doctors

Private and Confidential


Digital SnapShot of Your Health

SnapShot is a user-friendly results delivery system that capitalises on market trends and consumer expectations. The device will work to analyse blood markers across health categories including, for example:



SnapShot is both an off-the-shelf and white-label solution (including API functionality) offering an E2E service.

This includes fulfilling the blood test kits, delivering to the customer including returns, processing of samples and release of results.




2022E Product Offering

Tentative Launch Dates	Product Offerings	SKUs	Biomarkers Tested
End of Q1	Food Sensitivity	Food Sensitivity Test (Basic)	96 Food IgG
		Food Sensitivity Test (Comprehensive)	204 Food IgG
	General Health	Heart Health	Lipids profile: HDL, LDL, Total Cholesterol, Trig/ HDL ratio, Hba1c
	Women's Fertility	Women's Fertility (Basic)	FSH, E2 (AMH)
	Men's Hormones	Men's Hormones (Basic)	Total Testosterone
Q2 (TBD)	Women's Hormones	Women's Perimenopause	FSH, LH, E2
		Women's Post-menopause	E2, Progesterone
	Women's Fertility	Women's Fertility (Comprehensive)	FSH, LH, E2, AMH, TSH, Free T4, Prolactin, Progesterone, Total T, SHBG
	Men's Hormones	Men's Hormones (Comprehensive)	Total T, FSH, LH (Progesterone, Prolactin)
	General Wellness	Metabolism (Thyroid)	TSH, Free T3, Free T4
	General Wellness	Stress	Cortisol x4, Cortisone x4
Q3 (TBD)	General Wellness	Men's Health Complete	Free T, Total T, E2, Cortisol, DHEA, SHBG, Thyroid panels
	General Wellness	Women's Health Complete	FSH, LH, E2, AMH, TSH, Free T4, Progesterone, Total T, SHBG, Thyroid panels, Cortisol
Q4 (TBD)	STI	HIV (Screening & Confirmation) HPV	HIV HPV
	STI	STI Complete	Chlamydia, Gonorrhoea, Syphilis, Trichomoniasis, HIV, HSV2, Hep C

Circle App

- Review test results and recommendations
- Personalized digital health coach based on your DNA & biochemistry profile
- Track health status with regular screening tests
- Physician-backed and inspirational health tips to take your next steps




A Snapshot of
Your Health,
at your
Fingertips.



Private and Confidential

Diagnostics




Circle Medical Genetic Testing for Physicians

Launching in 2023E

Source: Frost & Sullivan. Notes: 1. Global market size for clinical molecular test service based on projection for 2030; Covid-19 testing service market is not included while influence of Covid-19 has been considered in the market sizing.

Moving into Medical Genetic Testing (Circle Medical) – Launching in 2023E

Revealing the cause of genetic diseases | Targeted and symptoms-based diagnostic testing





Product and Technology

Personalized Care

Personalized Care



Circle One / F1x / Fem Testing into personalized care




Launching in 2023E





Source: Frost & Sullivan.

Notes: 1. Based on CircleDNA customer survey conducted in Feb 2020. 2. Represents global target addressable market for hair loss and erectile dysfunction and global market size for personalized nutrition based on projection for 2030.




How It Works



DNA Profile Based Personalized Nutrition

Major Approaches to Achieve Personalized Nutrition		
Comparison	DNA Profile Based Personalized Nutrition	Questionnaire Based Personalized Nutrition
Definition	Healthcare that is based on an individual's genetic profile	Healthcare that use questionnaires
Object	Gene variations	Habits of lifestyle including sport, diet, etc.
Accuracy		
Cost		
Examples	Consumers with variants of <i>FTO</i> gene (which affects carbohydrates), are recommended with a diet of higher carbohydrate intake	Recommendations of food balance according to diet and sport habits

Benefits of DNA Profile Based Personalized Nutrition

 <p>Personalization: offers nutritional advice, products or services tailored to each individual's needs</p>	 <p>Health Management: ensures consumers have a stronger sense of participation in their own health management</p>	 <p>Comprehensive Health-related Information: assessment of disease risk based on user's DNA profile</p>
--	--	--

- The growth drivers of the DNA profile based personalized nutrition market primarily include increasing need for improving health and preventing diseases due to unhealthy lifestyle, rising awareness of the benefits of healthcare services, consumption upgrade and preference for high-quality diets and personalized services, and technological advancement

Illustrative Telehealth Journey – Planned Launching in 2022E



Near-term Plan

Personalized Supplements

\$10B+¹

- Unique formulas to meet individual genetic variations
- Supplements tailored to each individual's unique biology



MONTHLY RECURRING REVENUE



Future Solutions

Circle F1x / Fem

- Hair loss, erectile dysfunction, etc.



\$366B+²

Source: Frost & Sullivan.


1. Global market size for personalized nutrition based on projection for 2030. 2. Global target addressable market for hair loss and erectile dysfunction for 2030.



Financial Summary

Prenetics Continues To Transform Itself, Now At An Incredible Rate

Revenue Evolution¹



Multiple Shots on Goal, While Benefiting from Significant Customer and Operational Synergies Across Platform

Notes: USD/HKD FX rate of 7.78. For financial projections, please refer to the "Use of Projections" portion of the disclaimer. 1. 2019 and 2020 financials based on audited accounts – Prevention segment revenue includes other service fees and adjustments. 2021 and 2025 financials based on management forecast.

Driven by Robust Organic Growth and Product Launch Strategies

Revenue in US\$ millions

Product Launch Year




Notes: USD/HKD FX rate of 7.78. For financial projections, please refer to the "Use of Projections" portion of the disclaimer.
 1. 2019 and 2020 financials based on audited accounts – Prevention segment revenue includes other service fees and adjustments. 2021-2025 financials based on management forecast.

COVID-19: An Opportunity to Better Reimagine Healthcare

Revenue in US\$ millions¹

We conservatively assumed COVID-19 testing market is not here to stay. Instead, it has allowed us the opportunity to build the tools and expand our platform in order to better serve the new world order of healthcare



- Testing the New Norm
- Self Care as Necessity
- New Technology
- Brand & Trust
- Network
- Time to Market

Notes: USD/HKD FX rate of 7.78. For financial projections, please refer to the "Use of Projections" portion of the disclaimer.
 1. 2019 and 2020 financials based on audited accounts – Prevention segment revenue includes other service fees and adjustments. 2021-2025 financials based on management forecast.

High Operating Efficiency Leading to High Growth

Financials in US\$ million ¹	2019A	2020A	1H21A	2021E	2022E	2023E	2024E	2025E
Revenue	9	65	136	205	272	307	429	640
YoY %	NA	606%	1039%	215%	33%	13%	40%	49%
Gross Profit ²	3	27	57	85	118	137	185	295
Gross Margin %	33%	41%	42%	41%	43%	45%	43%	46%
Sales & Marketing Expenses ²	5	6	6	16	41	72	80	107
Research & Development Expenses ²	2	2	3	30	36	50	64	83
Administrative and Other Expenses ^{2,3}	9	14	17	19	27	36	48	65
Adjusted EBITDA (Non-GAAP)	(12)	4	31	21	14	(21)	(7)	39
Adjusted EBITDA Margin %	(131%)	7%	23%	10%	5%	(7%)	(2%)	6%
Depreciation and Amortization	2	2	2	8	13	17	20	21
ESOP & Other Non-Operating Expenses ⁴	6	4	37	54	16	18	25	37
Net Profit / (Loss)	(20)	(2)	(8)	(41)	(15)	(56)	(52)	(19)
Net Profit Margin %	(219%)	(3%)	(6%)	(20%)	(6%)	(18%)	(12%)	(3%)

- Revenue growth driven by robust organic expansion and product launch strategies



- Significant market opportunity in multiple verticals; Pipeline products expected to benefit from customer and operational synergies across platforms

- Significant positive momentum is expected from 2024 onwards as most products are in their high growth stage

Notes: USD/HKD FX rate of 7.78. For financial projections, please refer to the "Use of Projections" portion of the disclaimer. 1. 2019 and 2020 financials based on audited accounts. 2021-2025 financials based on management forecast. 2. Excludes depreciation and amortization expenses and a portion of ESOP. 3. Profit sharing to New Horizon for ColoClear is also included. 4. Non-operating expenses primarily attributable to fair value adjustments for ESOP and convertible securities issued by the Company. Includes tax expense and tax credit.

Well Capitalised with Strong Balance Sheet

Financials in US\$ millions



Leverage

Nil
Bank Borrowings

Private and Confidential

Peers' Proven Successes Supported by Substantial Valuation

	Prenetics Products	Peers ¹	Current Valuation / Market Capitalization ²
Prevention			\$4.0bn ³
			\$1.9bn ³
Diagnostics			\$1.6bn ³
			\$2.9bn ⁴
			\$4.4bn ³
Personalized Care			\$5.0bn ⁵

Source: Bloomberg. Notes: 1. Select companies with comparable products focused in the US / China. 2. Market cap for listed companies, or latest private round valuation. 3. Market cap as of November 17, 2021. 4. Valuation after the acquisition of PWNHealth; per Bloomberg, as of March 2021. 5. Post-money valuation for \$500mm fundraising; per Bloomberg, as of March 2021.

Prenetics' Proven M&A Track Record

Approach to Strategic Acquisitions and Collaborations

- ✓ Deployment of a structured and thoughtful process toward selecting the right acquisition targets with the best technological fit and cultural chemistry
- ✓ Focused on opportunities that provide the right platform or advanced technology to (1) expand product offerings, (2) attract more customers, and (3) enhance global presence

Acquisition of DNAFit (2018)

- Provided us the opportunity to grow business in the UK
- Currently, the UK operations contributes c.50% of the total revenue

Acquisition of Oxsed (2020)

- Provided us the support of nucleic acid amplification technologies ("NAAT"), the technological building block to Circle HealthPod

Strategic Collaboration with Oxford University

- OSCAR – Oxford Suzhou Centre
- Oxford University 3-Year Research Grant

Strategic Collaboration with New Horizon

- Provided us the exclusive rights to sell and process ColoClear in Hong Kong, Macau, and the Philippines
- Launch of ColoClear expected in 1H 2022E

We plan to continue to selectively pursue business combination and collaboration opportunities in a highly disciplined manner



Commercialization & Strategy

Prevention



Leading Brand

In Asia and UK consumer genomics

45-50x

More data than the competitors

120k+

CircleDNA tests delivered since July 2019 launch

\$16bn+

Global Market Size¹

\$19mm

2021E CircleDNA Projected Revenue

34%

2020A-2025E Revenue CAGR

CircleDNA

One of The World's Most Comprehensive Consumer DNA Test

Source: Frost & Sullivan; Notes: 1. Global market size for DTC molecular testing services based on projection for 2030; Covid-19 testing service market is not included while influence of Covid-19 has been considered in the market sizing.

Private and Confidential

CircleDNA — An All-New Industry Standard in Genetic Testing



Vital

- 14 Categories – 125 Reports
- Diet, Nutrition, Fitness, Stress, Ancestry, Skin, and More
- 30 Mins Phone Consultation

Retail Price

USD 189



Family Planning

- 1 Category – 163 Reports
- Carrier Screening of recessive genetic diseases
- 30 Mins Phone Consultation

USD 499



Health

- 4 Categories – 115 Reports
- Cancer, Common Health Risks, Disease Risks, Dementia & Brain Health
- 30 Mins Phone Consultation

USD 499



Premium

- 20 Categories – 500+ Reports
- Vital + Family Planning + Health Bundle + Drug Response
- 30 Mins Phone Consultation (2x)

USD 629

Private and Confidential

CircleDNA Marketing Strategy

Celebrity Ambassadors



Vaness Wu
Actor & singer

15M+ social media followers



G.E.M.
Asia's Taylor Swift

50M+ social media followers



Gigi Leung
Actor, singer & mother

20M+ social media followers

ATL Marketing



TRAM



WATSONS



TAXI



BILLBOARD

Social Media




Private and Confidential

CircleDNA — Extraordinary Growth with Significant Runway

Forecasted Growth Trajectory after Launch¹


(# of Cumulative Tests Sold, '000)

Market cap of **\$4.0bn²**



CircleDNA Revenue

(US\$ millions)



Market Size⁴

US\$8.8 bn

APAC / EMEA
Consumer DNA Test

Market Size⁴

US\$5.1 bn

US Consumer DNA Test

Source: Frost & Sullivan, Trust Pilot Review. Notes: 1. Blue dotted line denotes management forecast; grey dotted line is extrapolation of 23andMe. 2. Market data as of November 17, 2021. 3. As of July 12, 2021. 4. Market size for DTC molecular testing services based on projection for 2030; Covid-19 testing service market is not included while influence of Covid-19 has been considered in the market sizing.

Prevention



96%

Sensitivity -
Highly Accurate

**Cost
Effective**

Comparing to
Colonoscopy

**Successful
Model**

Comparable to
ColoGuard
in the US

\$101bn+

Addressable
market¹

ColoClear


The Only Non-Invasive Colon
Cancer Screening Test Approved
by NMPA

Launching in 1H 2022E


Source: Frost & Sullivan. Notes: 1. Global target addressable market for colorectal cancer screening based on projection for 2030, except for mainland China; target population is the age group of 40-74 years old. **Private and Confidential** 66

Significant Whitespace in Asia Markets Presents Attractive Growth Opportunities


Colorectal Cancer Screening Market in US (2019)



Colorectal Cancer Screening Market in HK & SEA (2019)



Revenue of ColoGuard for Exact Sciences¹ (US\$ mm)



Projected Revenue of ColoClear for Prenetics (US\$ mm)



Source: Frost & Sullivan. Notes: 1. Before Exact Science's acquisition of Genomic Health in November 2019, ColoGuard is the only major revenue source for Exact Sciences. 2. Market data as of November 17, 2021. 67

Strategic Technology Transfer from New Horizon to Launch ColoClear

Prenetics™



(Listed on HKEX with market cap of **US\$1.9bn**¹ and FY2020 revenue of US\$10mm)

Exclusive

Exclusive rights granted to sell & process ColoClear in Hong Kong, Macau, and the Philippines; plan to expand to Taiwan and other countries and regions of SE Asia

50:50

Under a profit sharing agreement, Prenetics and New Horizon **will equally share gross profits**² from sales of ColoClear

5+5 Years

5 years of initial term renewable for another **5 years** by mutual consent

Technology Transfer

Completed technology transfer from New Horizon; **certified by New Horizon to perform ColoClear testing at its lab**

Establishment of Strategic Partnership with New Horizon Health to Commercialize ColoClear

Source: Company Filings. Notes: USD/HKD FX rate of 7.78. 1. Market data as of November 17, 2021. 2. Gross profit = Gross Revenue – COGS for products sold – COGS for lab testing services – Sales & Marketing Expenses (including sales incentive and logistics costs).

Strategic Partnership with EC Healthcare to integrate all of Prenetics testing products as a service offering to EC Healthcare's patients

Prenetics™



(Listed on HKEX with market cap of **US\$1.8bn**¹ and FY2020 revenue of US\$267mm)

Exclusive

Exclusive rights granted to market and sell Prenetics' testing products in Hong Kong and Macau

Market Leader

EC Healthcare is Hong Kong's **largest** non-hospital medical group

R&D

EC Healthcare and Prenetics to jointly develop necessary IT solutions to enhance the **integration of health data resources and genomics data resources**

Future of Medicine

Collaboration aims to enable preventive & precision medicine, drug discovery and health policy steering for governments

Source: Company Filings. Notes: USD/HKD FX rate of 7.78. 1. Market data as of November 17, 2021. 2. Gross profit = Gross Revenue – COGS for products sold – COGS for lab testing services – Sales & Marketing Expenses (including sales incentive and logistics costs).

Diagnosics



Prenetics laboratory inside Hong Kong International Airport

Project Screen

Covid-19 Testing



Source: Frost & Sullivan.
Notes: 1. As October 31, 2021. 2. Based on projection for 2021; represents global market size; only consists of tests performed in independent clinical laboratories.

Prenetics Response To Covid-19

Key Highlights

HK Government

- ~4M tests serviced for HK government
 - ✓ Community Testing
 - ✓ Quarantine Hotels
 - ✓ Hospital Authority
 - ✓ Department of Health
 - ✓ Food and Environmental Hygiene Department (FEHD)



English Premier League

- Provides daily testing service for more than 3,000 players and club staffs for English Premier League on a regular basis



Airport Testing to International & Local Airports

- Airport testing in Hong Kong and the United Kingdom, including HKIA¹, Heathrow, Manchester, Stansted, London City, and East Midlands airports
- Converted smoking lounge to an ISO-15189 laboratory at the HKIA¹. Prenetics is the only Covid-19 testing provider with operating lab in HKIA¹



Extensive Partnerships Across Sectors

Prenetics + Virgin Atlantic

- Prenetics has become Virgin Atlantic's preferred at-home testing provider, with customers able to order a complete end-to-end travel testing bundle, tailored to their destination

Travel (2022E Revenue \$89M)

Virgin Atlantic, Carnival Cruise Line, Cruise line operation of an entertainment company, Hong Kong International Airport, Heathrow Airport, London Luton Airport, London Stansted Airport, Manchester Airport, Gatwick Airport, London City Airport, East Midlands Airport


Entertainment & Sports (2022E Revenue \$15M)

English Premier League, Professional Darts Corporation, England and Wales Cricket Board, British Academy Film Awards, Sky TV, Global Media & Entertainment Company, American Film & TV Studio

Note: 1. Hong Kong International Airport.

Significant Upside as Travel “Resumes”

Covid-19 Testing Revenue Breakdown (US\$ millions)



Source: Frost & Sullivan. Notes: 1. 2020 financials based on management accounts – excludes airline & cruises revenue in EMEA as breakdown is not available. 2. Include entertainment & sports, community testing & screening, corporate B2B testing, etc. 3. Based on projection for 2021; represents global market size; only consists of tests performed in independent clinical laboratories.

Diagnostics



Detects Covid-19 with NAAT
PCR-Quality Technology



Future Assays:

- Influenza / Flu
- STDs

<30min

Time to result

98.4%²

Concordance with the q-PCR test

\$849bn+

Global Market Size¹

Mobile & Scalable

No lab or specialist equipment

Painless

Pain-free nasal swab

CE-IVD Marked

Expect to receive US FDA EUA by 1H 2022

Circle HealthPod
A Lab. In Your Pocket

Officially Launched in Hong Kong Nov 2021
Expected to be launched in the EU, the US, and Southeast Asia

Source: Frost & Sullivan. Notes: 1. Represents global market size for medical device based on the projection for 2030. 2. According to trials done primarily by professors and scientists of University of Oxford.

Circle HealthPod Product Offering



Trial Set

- 1 x Circle HealthPod
- 1 Free Single-use Capsule

HKD 990

USD 127



Starter Set

- 1 x Circle HealthPod
- 5 x Single-use Capsule + 1 Free

HKD 1,649

USD 212



Family Set

- 2 x Circle HealthPod
- 10 x Single-use Capsule + 2 Free

HKD 2,910

USD 374



Single-use Capsule Set

- 5 x Nasabl Swabs
- 5 x Molecular Capsules
- 5 x Specimen Capsules

HKD 810

USD 104

Notes: USD/HKD FX rate of 7.78.

Circle HealthPod B2B Stations

Multiple Circle HealthPods



Circle HealthPod Dashboard



Type of Test	Date	Test Result
Covid-19 Test	May 04, 2020, 15:18	Positive
Covid-19 Test	May 05, 2020, 20:02	Positive
Covid-19 Test	May 06, 2020, 14:32	Positive
Covid-19 Test	May 06, 2020, 13:40	Positive
Covid-19 Test	May 06, 2020, 22:11	Positive
Covid-19 Test	May 08, 2020, 16:40	Positive

PartnersApp



Single-use Specimen Capsule



Capacitor



Use Case



Private Use

- At-home testing
- On the go testing (with portable charger)



Hospitals & Clinics

- In-patient and out-patient on-site screening
- Regular testing for healthcare workers & family



Hotels & Apartments

- For hotel guests as a complimentary item for their stay or as a paid in-room service
- Must-have for every homes to for a peace of mind



Schools

- Rapid testing for schools
- Regular testing for students and teachers



NGO Community Screen

- Easy and simple test for NGO's
- Regular testing for community members



Sports & Entertainment

- Rapid at-home testing for attendees
- Regular testing for players and staffs

Circle HealthPod Marketing Strategy

Celebrity Ambassadors



Donnie Yen
World-Renowned
Filmmaker

2.2M+
social media followers



Ian Chan
Singer-Songwriter

400k+
social media followers



Grace Chan
Miss Hong Kong 2013

704k+
social media followers



Cecilia Yeung
High Jump Record
Holder

120k+
social media followers

ATL Marketing



TRAM



MTR



Billboard



TVC



TAXI



BUS STATION

Concept Stores



Circle K11 MUSEA



Circle Hysan Place

Notes: 1. Number of Instagram followers as of Nov 23, 2021.

Successful Commercialization Case Study: Cue Health

The Cue Health Monitoring System

- The Cue Health Monitoring System is a fast, compact, highly portable testing platform with high performance and accuracy, utilizing molecular diagnostic technology
- Cue Health's COVID-19 cartridge test is authorized by the US FDA for home use with no prescription in Mar 2021. The company filed for a US IPO on September 1, 2021

Cue Health awarded \$481 million to scale up production of COVID-19 test: HHS



REUTERS



HHS launches pilot program in five states using rapid Covid test deployed by NBA



Go-to-Market Strategy: Key Partners & Target Clients

Public Sector

US Department of Defense
Government Agencies

Enterprise

Henry Schein
Fortune 500 Companies

Healthcare Provider

Mayo Clinic
Hospitals / Private Clinics

Direct-to-Consumer

E-commerce
In-store

Source: Factset, Company Filings, Cue Health Company Website, Bloomberg, Reuters, CNBC.
Notes: 1. Market data as of November 17, 2021.

Diagnostics



Circle SnapShot

Your annual health check at home



Launching in 2022E

Source: Frost & Sullivan. Notes: 1. Global market size for at-home health testing based on projection for 2030; does not include home testing kits which do not require lab tests; Covid-19 at-home test has not been considered.

Successful Commercialization Case Study: Everlywell

Innovative at-home Health Testing

- Everlywell's portfolio of 30+ at-home tests offer simple sample collection and physician-reviewed results and insights sent to your device in 5 to 7 business days
- In March 2021, Everlywell announced its acquisition of PWNHealth and Home Access Health Corp. in a cash and stock deal. The combined companies, re-branded as Everly Health, expects to support more than 20 million people annually in the US

\$2.9bn

Valuation¹

Popular Everlywell Tests

Food Sensitivity

Measure body's immune systems' IgG antibody reactivity to 96 foods



Metabolism

Measure free testosterone, cortisol and TSH levels



Indoor & Outdoor Allergy

Test for 40 common indoor and outdoor allergens



Sexually Transmitted Disease

Screens for 7 common sexually transmitted infections




~\$200mm

2020 Revenue¹

Source: Everlywell Company Website, Bloomberg. Notes: 1. Per Bloomberg news article, as of March 2021.

Diagnostics




Circle Medical Genetic Testing for Physicians

Launching in 2023E

Source: Frost & Sullivan. Notes: 1. Global market size for clinical molecular test service based on projection for 2030; Covid-19 testing service market is not included while influence of Covid-19 has been considered in the market sizing.

Significant Growth Potential in Asia / Europe Markets Present Attractive Growth Opportunities

Medical Molecular Testing Market in US (US\$ bn)



Medical Molecular Testing Market in HK / SEA / Europe (US\$ bn)



Revenue for Invitae (US\$ mm)




Projected Revenue of Circle Medical for Prenetics³ (US\$ mm)



Source: Frost & Sullivan.

Notes: 1. Billable volume for 2018 – 2019. Accessioned volume for 2017. 2. Market data as of November 17, 2021. 3. While its geographic scope is not limited to certain regions, it is expected to predominantly generate revenue in Hong Kong, SE Asia and Europe during the projection period.

Personalized Care



Circle One / F1x / Fem Testing into personalized care



Launching in 2023E

Source: Frost & Sullivan.

Notes: 1. Based on CircleDNA customer survey conducted in Feb 2020. 2. Represents global target addressable market for hair loss and erectile dysfunction and global market size for personalized nutrition based on projection for 2030.

Successful Commercialization Case Study: Roman

Roman – Digital Health Clinic for Men

- Roman provides personalized solutions to men for the treatment of erectile dysfunction, hair loss, premature ejaculation, etc.
- Roman's daily vitamins and supplements are available in 4,600+ Walmart stores across the United States



Bloomberg

Online Pharmacy Ro Is Said to Raise Funds at \$5 Billion Value

Online pharmacy and health technology company Ro has raised \$500 million in new funding, its chief executive officer told Bloomberg News.

FORTUNE

Telehealth startup Ro partners with Pfizer to give its ED business a boost

Key Partners

Sports & Entertainments

MLB

Pharmaceuticals

Pfizer
Greenstone

Retailers

Walmart

Healthcare

Ribbon Health
Quest Diagnostics


Source: Roman Company Website, Bloomberg, PR Newswire, Fortune.

Notes: 1. Per Bloomberg, as of March 2021. Represents the post-money valuation of Ro, the operator of Roman.
2. Per Bloomberg, as of March 2021. Represents the lifetime fundraising of Ro, the operator of Roman.




Closing Remarks

Prenetics Delivering Favorable Metrics vs. US Peers 5 Years Ago




Notes: USD/HKD FX rate of 7.78. 1. 2021-2025 financials based on management forecast. Exact Sciences, Invitae and Natera historical financials sourced from company filings. 2. Indicates primary product focus. 3. Please refer to Transaction Summary page for further details. 4. Market data as of December 31, 2016. 5. Market data as of November 17, 2021.

Tremendous Value Potential for Prenetics to be Unlocked via Synergistic Acquisitions




Notes: 1. Market data as of December 31, 2016. 2. Market data as of November 17, 2021. 3. Please refer to Transaction Summary page for further details.
Private and Confidential

Prenetics is Building the Future of Healthcare




























Appendix

Benchmarking Analysis




Source: Company disclosures, broker reports and FactSet as of November 17, 2021; 1.Prenetics' EV/revenue multiples are based on illustrative enterprise value of \$1.254bn.

Select Precedent Transactions

Date	Acquiror	Target	Public / Private	EV ¹ (US\$m)	EV/LTM	
					Sales (x)	EBITDA (x)
Nov-21	 23andMe	 Lemonaid	Public	453.9 ²	–	–
Sep-21	 Oncology	OMNIGENE	Private	714.8	–	–
Aug-21	illumina	GRAIL (85.5%)	Private	7,100.0	–	–
Apr-21	HOLOGIC	MOBIDING	Private	795.0	18.9	–
Apr-21	 HEALTHCARE	 lumira	Private	3,000.0	–	–
Apr-21	 DaScribe	Luminex	Public	1,624.3	3.9	22.3
Mar-21	 VIG	 GenVec	Public	1,729.0	10.1	–
Feb-20	 EXACT SCIENCES	 Thrive	Private	3,500.0	11.5	–
Oct-20	 EXACT SCIENCES	 base	Private	1,700.0	–	–
Oct-20	 investor	 ADVANCED	Private	410.0	–	–
Sep-20	 investor	 VOLVOX (80%)	Private	780.0	10.8	24.1
Sep-20	 INVITAE	ARCHER	Private	309.6	–	–
Jun-20	 INVITAE	 diplod	Private	886.0	17.7	nm ³
Mar-20	 meridian	 Exalenz	Private	95.0	–	–
Feb-20	 meridian	 Exalenz	Public	51.5	3.8	nm ³
Jan-20	 NEO	 EDMAN LONGEVITY INC (Oncology)	Private	37.0	3.7	–
Mean				1,449.1	10.1	23.2
Median				787.5	10.5	23.2

Sources: Public filings, Dealogic and MergerMarket. Notes: 1. Excludes earnout; 2. Lemonaid's EV is based on cash consideration of US\$102m and share consideration of 23andMe's 30,0278,958 Class A common stock as disclosed in 23andMe's 10-Q for Q2 2021. The share consideration portion is calculated with 23andMe's closing share price on date of announcement of the completion of acquisition (November 1, 2021); 3. EV / LTM EBITDA multiple less than 0.0x.

Near-term Development of Product Pipeline



Risks Relating to Prenetics' Business

Risks Relating to Doing Business in Hong Kong

1. The business, financial condition and results of operations of Prenetics, and/or the value of PubCo's securities or PubCo's ability to offer or continue to offer securities to investors may be materially and adversely affected to the extent the laws and regulations of the PRC become applicable to Prenetics. In that case, Prenetics may be subject to the risks and uncertainties associated with the evolving laws and regulations in the PRC, their interpretation and implementation, and the legal and regulatory system in the PRC more generally, including with respect to the enforcement of laws and the possibility of changes of rules and regulations with little or no advance notice.
2. The PRC government has significant oversight, discretion and control over the manner in which companies incorporated under the laws of PRC must conduct their business activities, but as Prenetics operates in Hong Kong and not mainland China, the PRC government currently does not exert direct oversight and discretion over the manner in which Prenetics conducts its business activities. However, there is no guarantee that the PRC government will not seek to intervene or influence Prenetics' operations at any time. If Prenetics were to become subject to such oversight, discretion or control, including over overseas offerings of securities and/or foreign investments, it may result in a material adverse change in Prenetics' operations, significantly limit or completely hinder PubCo's ability to offer or continue to offer securities to investors and cause the value of PubCo's securities to significantly decline or be worthless, which would materially affect the interests of the investors.
3. Implementation of the National Security Law in Hong Kong involves uncertainty, and the recent policy pronouncements by the PRC government regarding business activities of U.S.-listed Chinese businesses may negatively impact Prenetics' existing and future operations in Hong Kong.
4. PubCo's securities may be delisted or prohibited from being traded "over-the-counter" under the Holding Foreign Companies Accountable Act if the PCAOB were unable to fully inspect or investigate Prenetics' auditor. The delisting or the cessation of trading "over-the-counter" of PubCo's securities, or the threat of their being delisted or prohibited, may materially and adversely affect the value and/or liquidity of your investment. Additionally, if the PCAOB were unable to conduct full inspections or investigations of Prenetics' auditor, it would deprive PubCo's investors of the benefits of such inspections or investigations.
5. Prenetics may be affected by the currency peg system in Hong Kong and other exchange rate fluctuations.
6. Increases in labor costs may adversely affect Prenetics' business and results of operations.
7. Unfavorable economic and political conditions in Hong Kong and other parts of Asia could materially and adversely affect Prenetics' business, financial condition, and results of operations.

Key Risks Relating to Prenetics' Business

1. A significant portion of Prenetics' historical revenue was, and its near-term revenue will be generated, from its COVID-19 testing services, the demand for which may be substantially reduced with the production and widely administered use of an efficacious vaccine or treatment for COVID-19, and failure of Prenetics to derive significant revenue from other products and services and expand its overall customer base would harm its business and results of operation.
2. The diagnostic testing market, particularly with respect to COVID-19 testing, is highly competitive, and many of Prenetics' competitors are larger, better established and have greater financial and other resources.
3. The consumer genetic testing market is highly competitive, and many of Prenetics' competitors are more established and have stronger marketing capabilities and greater financial resources, which presents a continuous threat to the success of its consumer genetic testing business.
4. Prenetics' near-term success is highly dependent on the successful launch of Circle HealthPod and the continued commercialization of its COVID-19 testing services in its target geographies. If Prenetics' existing or new products are unable to attain market acceptance or be successfully commercialized in all or any of these jurisdictions, its business and future prospects could be materially and adversely affected.
5. Prenetics relies substantially on third-party contract manufacturers for the manufacturing, quality-testing, assembly and shipping of its COVID-19 test kit, Circle HealthPod and other products. Any termination of significant rights under the existing arrangements would disrupt Prenetics' ability to sell and distribute its COVID-19 test kit, Circle HealthPod and other products until and unless it finds new contract manufacturers, which would materially and adversely affect its business.
6. Prenetics has a number of pipeline products that are currently in the R&D phase, including Circle Medical, Circle SnapShot, future assays of Circle HealthPod, Circle One and F1x and Fern, and may not be successful in its efforts to develop any of these or other products into marketable products. Any failure to develop these or other products or any delay in the development could adversely affect its business and future prospects.
7. Clinical trials, and verification and validation studies necessary to support a future product submission with regulatory authorities will be expensive and may require the enrollment of large numbers of subjects or the availability of a large number of test samples, and suitable subjects or samples may be difficult to identify and recruit or obtain. Delays or failures in Prenetics' clinical trials will prevent it from commercializing any modified or new products and will adversely affect its business, operating results and prospects.
8. If the third parties engaged by Prenetics to conduct clinical trials fail to render their services as contractually required or expected, Prenetics may not be able to obtain regulatory approval for or commercialize its products.
9. If Prenetics is not successful in leveraging its platform and technology to discover, develop and commercialize additional products, its ability to expand its business and achieve its strategic objectives would be impaired.
10. If Prenetics' products and services do not deliver reliable results as expected, its reputation, business and operating results will be adversely affected.

Risks Relating to Prenetics' Business (Cont'd)

Other Risks Relating to Prenetics's Business

1. Prenetics has incurred net losses since its inception, and it anticipates that it will continue to incur losses for the foreseeable future, which could harm its future business prospects.
2. Prenetics is an early-stage company and has a limited operating history, and its near-term business strategy and in-house R&D efforts are centered around new and rapidly developing markets including point-of-care testing (POCT) for infectious diseases diagnosis, which may make it difficult to evaluate its current business and predict its future performance.
3. Prenetics has a limited history introducing new products and services to its customers. The future prospects of its business may be harmed if Prenetics' efforts to attract new customers and engage existing customers by introducing new products, including Circle HealthPod, are unsuccessful.
4. Prenetics may not be able to achieve or maintain satisfactory pricing and margins, and its pricing strategies may not meet customers' price expectations, which could adversely affect its revenues and results of operations. Prenetics has increased, and expects to further expand, the size of its organization, and it may experience difficulties in managing its growth. If Prenetics is unable to manage the anticipated growth of its business, its future revenue and operating results may be harmed.
5. Prenetics has increased, and expects to further expand, the size of its organization, and it may experience difficulties in managing its growth. If Prenetics is unable to manage the anticipated growth of its business, its future revenue and operating results may be harmed.
6. The initial use of Prenetics' test kits requires users to follow instructions, and not adhering to instructions may lead to false results and inaccurate outcomes, which could harm the user experience and customer perception of Prenetics' products.
7. Some of Prenetics' marketing initiatives, including celebrity and key opinion leader endorsement and use of social media, may adversely affect Prenetics' reputation. Prenetics relies substantially on its research collaboration with Oxford for development and commercialization of its POCT infectious disease testing products. If Oxford is unable to achieve projected development milestones or produce any meaningful research results, or experiences delays in doing so, Prenetics may not be able to capitalize on its investment in the collaboration projects and its business and reputation may be adversely affected.
8. Prenetics relies substantially on its research collaboration with Oxford for development and commercialization of its POCT infectious disease testing products. If Oxford is unable to achieve projected development milestones or produce any meaningful research results, or experiences delays in doing so, Prenetics may not be able to capitalize on its investment in the collaboration projects and its business and reputation may be adversely affected.
9. Prenetics relies on a limited number of suppliers for Circle HealthPod components, COVID-19 test kit materials and laboratory testing services for COVID-19 test kit and CircleDNA, and may not be able to find replacements or immediately transition to alternative suppliers, which could adversely affect its ability to meet customer demand.
10. The operating results of Prenetics may fluctuate significantly, which makes its future operating results difficult to predict and could cause its operating results to fall below expectations.
11. Prenetics' business significantly depends upon the strength of Prenetics' brands, including Prenetics, CircleDNA and Circle HealthPod, and any harm to Prenetics' brands or reputation may materially and adversely affect its business and results of operations.
12. If Prenetics cannot provide quality technical and customer and user support, it could lose customers, and its business and prospects may be adversely affected.
13. If Prenetics is unable to successfully expand its sales and marketing infrastructure to match its growth, its business may be adversely affected.
14. Prenetics is highly dependent on its senior management team and key advisors and personnel, and its business and operating results could be harmed if it is unable to retain senior management and key personnel and to attract and retain qualified personnel necessary for its business.
15. The sizes of the markets and forecasts of market growth for the demand of Prenetics' current and pipeline products and services are based on a number of complex assumptions and estimates that are subject to change, and may be inaccurate.
16. Prenetics may need to raise additional funds to develop its platform, commercialize new products or expand its operations, and it may be unable to raise capital when needed or on acceptable terms.
17. Prenetics plans to enter new business areas, such as clinical genetic testing and personalized care, where Prenetics does not have any experience or has minimal experience. Prenetics would likely face competition from entities more familiar with those businesses, and Prenetics' efforts may not succeed.
18. Prenetics may engage in acquisitions, investments or strategic alliances in the future, which could require significant management attention and resources, may not achieve their intended results and could adversely affect its business, financial condition and results of operations.
19. Prenetics may incur debt or assume contingent or other liabilities or dilute Prenetics' shareholders in connection with acquisitions or strategic alliances.
20. If PubCo fails to implement and maintain an effective system of internal controls in the future, PubCo may be unable to accurately report its financial condition or results of operations, which may adversely affect investor confidence in Prenetics and, as a result, the market price of PubCo Ordinary Shares and PubCo Warrants.
21. U.K.'s withdrawal from the European Union could have an adverse impact on Prenetics' business.
22. If Prenetics, its suppliers or its contract manufacturers experience any significant business disruptions, Prenetics' operations and financial condition could be seriously harmed.
23. Prenetics depends on the information systems of its own and those of third parties for the effective service on Prenetics' website, mobile applications, or in Prenetics' computer or logistics systems, and the overall effective and efficient functioning of its business. Failure to maintain or protect Prenetics' information systems and data integrity effectively could harm Prenetics' business, financial condition and results of operations.
24. The COVID-19 pandemic could materially and adversely affect Prenetics' business and results of operations.

Risks Relating to Prenetics' Business (Cont'd)

Risks Relating to Government Regulation

1. Prenetics' business collects and processes a large amount of data including personal information, and Prenetics will face legal, reputational, and financial risks if Prenetics fails to protect its customers' data from security breaches or cyberattacks. Prenetics is also subject to various laws and regulations relating to privacy or the protection or transfer of data relating to individuals, and any change in such laws and regulations or any failure by Prenetics to comply with such laws and regulations could adversely affect Prenetics' business.
2. Prenetics' products and services are and will continue to be subject to extensive regulation, compliance of which could be costly and time-consuming or may cause unanticipated delays or prevent the receipt of the required approvals to offer Prenetics' products and services.
3. Prenetics' testing products are subject to various regulatory guidelines, and any identified deficiencies or quality issues in the components of the test kits and testing devices could result in product recalls and could harm its reputation, business and financial results.
4. Prenetics plans to expand its business and operations internationally to various jurisdictions in which it does not currently operate and where Prenetics has limited operating experience, all of which exposes Prenetics to business, regulatory, political, operational and financial risk.

Risks Relating to Intellectual Property and Legal Proceedings

1. Prenetics may be subject to legal proceedings and litigation, which are costly to defend, and adverse publicity about any investigation, litigation, regulatory or legal action against Prenetics or its senior management could harm its reputation and business.
2. Prenetics' patent and other intellectual property protection may not be sufficient, and if Prenetics is unable to obtain, maintain and protect its intellectual property rights and proprietary information or prevent third-parties from making unauthorized use of its technology, its business could be harmed.
3. Prenetics depends, and may depend in the future, on intellectual property licensed from third parties for development and commercialization of certain products, and the termination of the licenses or other agreements permitting Prenetics to use such intellectual property or failure of such third parties to maintain or protect such intellectual property could result in the loss of significant rights by Prenetics, which would harm its business.
4. Prenetics could be sued for products liability, which could result in substantial liabilities that exceed its resources.
5. Prenetics may be subject to claims that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that Prenetics' employees have wrongfully used or disclosed alleged trade secrets of their former employers.
6. The diagnostic testing industry is characterized by intellectual property litigation and in the future Prenetics may be involved in patent litigation or other intellectual property infringement claims or administrative proceedings with respect to intellectual property that could be costly, result in the diversion of management's time and efforts, and may disrupt its business and operations.
7. Patent terms may be inadequate to protect Prenetics' competitive position on its products and services for an adequate amount of time.
8. Prenetics uses open source software, which may pose particular risks to its proprietary software and source code. Prenetics may face claims from open source licensors claiming ownership of, or demanding the release of, the intellectual property that it developed using or derived from such open source software.
9. Prenetics relies substantially on its trademarks and trade names. If its trademarks and trade names are not adequately protected, then Prenetics may not be able to build name recognition in its markets of interest and its business may be harmed.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are based on beliefs and assumptions and on information currently available to Artisan Acquisition Corp. (“Artisan”) and Prenetics Group Limited (“Prenetics”) and also contains certain financial forecasts and projections.

All statements other than statements of historical fact contained in this document, including, but not limited to, statements as to future results of operations and financial position, Prenetics’ plans for new product development and geographic expansion, objectives of management for future operations of Prenetics, projections of market opportunity and revenue growth, competitive position, technological and market trends, the sources and uses of cash from the proposed transaction, the anticipated enterprise value of the combined entity (“PubCo”) following the consummation of the proposed transaction, anticipated benefits of the proposed transaction and expectations related to the terms of the proposed transaction, are also forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. These statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of Artisan and Prenetics, which involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Any such estimates, assumptions, expectations, forecasts, views or opinions, whether or not identified in this document, should be regarded as indicative, preliminary and for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. Although each of Artisan, Prenetics and PubCo believes that it has a reasonable basis for each forward-looking statement contained in this document, each of Artisan, Prenetics and PubCo caution you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there will be risks and uncertainties described in the proxy statement/prospectus on Form F-4 relating to the proposed transaction, which has been filed by PubCo with the U.S. Securities and Exchange Commission (the “SEC”) and other documents filed by Artisan or PubCo from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements in this document include statements regarding the proposed transaction, including the timing and structure of the transaction, the proceeds of the transaction and the benefits of the transaction. Neither Artisan, Prenetics nor PubCo can assure you that the forward-looking statements in this document will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including the ability to complete the business combination due to the failure to obtain approval from Artisan’s shareholders or satisfy other closing conditions in the business combination agreement, the occurrence of any event that could give rise to the termination of the business combination agreement, the ability to recognize the anticipated benefits of the business combination, the amount of redemption requests made by Artisan’s public shareholders, costs related to the transaction, the impact of the global COVID-19 pandemic, the risk that the transaction disrupts current plans and operations as a result of the announcement and consummation of the transaction, the outcome of any potential litigation, government or regulatory proceedings and other risks and uncertainties, including those to be included under the heading “Risk Factors” in the registration statement on Form F-4 that has been filed by PubCo to the SEC and those included under the heading “Risk Factors” in the final prospectus of Artisan dated May 13, 2021 and in its subsequent quarterly reports on Form 10-Q and other filings with the SEC. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Artisan, Prenetics, PubCo, their respective directors, officers or employees or any other person that Artisan, Prenetics or PubCo will achieve their objectives and plans in any specified time frame, or at all. The forward-looking statements in this document represent the views of Artisan, Prenetics and PubCo as of the date of this document. Subsequent events and developments may cause those views to change. However, while Artisan, Prenetics and PubCo may update these forward-looking statements in the future, Artisan, Prenetics and PubCo specifically disclaim any obligation to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of Artisan, Prenetics or PubCo as of any date subsequent to the date of this document. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Important Additional Information Regarding the Transaction Will Be Filed With the SEC

In connection with the proposed transaction, PubCo has filed a registration statement on Form F-4 (the "Registration Statement") with the SEC that includes a prospectus with respect to PubCo's securities to be issued in connection with the proposed transaction and a proxy statement with respect to the shareholder meeting of Artisan to vote on the proposed transaction. Shareholders of Artisan and other interested persons are encouraged to read, when available, the preliminary proxy statement/prospectus as well as other documents to be filed with the SEC because these documents will contain important information about Artisan, Prenetics and PubCo and the proposed transaction. After the Registration Statement is declared effective, the definitive proxy statement/prospectus to be included in the registration statement will be mailed to shareholders of Artisan as of a record date to be established for voting on the proposed transaction. Once available, shareholders of Artisan will also be able to obtain a copy of the Registration Statement, including the proxy statement/prospectus, and other documents filed with the SEC without charge, by directing a request to: Artisan Acquisition Corp., Room 1111, New World Tower 1, 18 Queen's Road, Central, Hong Kong. The preliminary and definitive proxy statement/prospectus to be included in the Registration Statement, once available, can also be obtained, without charge, at the SEC's website (www.sec.gov).

Participants in the Solicitation

Artisan, Prenetics and PubCo and their respective directors and executive officers may be considered participants in the solicitation of proxies with respect to the potential transaction described in this document under the rules of the SEC. Information about the directors and executive officers of Artisan and their ownership is set forth in Artisan's filings with the SEC, including its final prospectus dated May 13, 2021 and subsequent filings on Form 10-Q and Form 3. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of Artisan's shareholders in connection with the potential transaction will be set forth in the Registration Statement. These documents are available free of charge at the SEC's website at www.sec.gov or by directing a request to Artisan Acquisition Corp., Room 1111, New World Tower 1, 18 Queen's Road, Central, Hong Kong.

No Offer or Solicitation

This document is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and does not constitute an offer to sell or a solicitation of an offer to buy any securities of Artisan, Prenetics or PubCo, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.
